Bank of America: Novo-rival snubler i 2018

Eli Lilly kan blive den lille i kampen om det væsentligste vækstmarked inden for diabetes, hvis selskabet ikke formår at vise en reduktion i risikoen for at udvikle hjertekarsygdomme med diabetesmidle …

You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

You must be logged in to post a comment.

Powered by WordPress | Designed by: Premium Themes | Thanks to Free WordPress 4 Themes, Download Premium WordPress Themes and
%d bloggers like this: